Log in

NASDAQ:NKTXNkarta Stock Price, Forecast & News

$24.00
-0.89 (-3.58 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$23.60
Now: $24.00
$25.40
50-Day Range N/A
52-Week Range
$23.60
Now: $24.00
$58.69
Volume122,370 shs
Average Volume309,078 shs
Market Capitalization$706.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates include NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NKTX
CUSIPN/A
CIKN/A
Phone650-215-0385

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees62
Market Cap$706.32 million
Next Earnings DateN/A
OptionableNot Optionable
$24.00
-0.89 (-3.58 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Nkarta (NASDAQ:NKTX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Nkarta?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nkarta
.

What price target have analysts set for NKTX?

4 Wall Street analysts have issued 12 month price targets for Nkarta's stock. Their forecasts range from $34.00 to $55.00. On average, they anticipate Nkarta's share price to reach $43.33 in the next year. This suggests a possible upside of 80.6% from the stock's current price.
View analysts' price targets for Nkarta
.

Has Nkarta been receiving favorable news coverage?

News headlines about NKTX stock have been trending very positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nkarta earned a news impact score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Nkarta
.

Who are some of Nkarta's key competitors?

Who are Nkarta's key executives?

Nkarta's management team includes the following people:
  • Mr. Paul J. Hastings, CEO, Pres & Director (Age 60, Pay $784.07k)
  • Dr. Matthew James Plunkett, Chief Financial Officer (Age 48, Pay $467.65k)
  • Dr. Kanya Rajangam, Chief Medical Officer (Age 47, Pay $570.15k)
  • Mr. Ralph Brandenberger Ph.D., VP of Technical Operations (Age 51)
  • Dr. James Trager Ph.D., PhD, Chief Scientific Officer (Age 57)

When did Nkarta IPO?

(NKTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities served as the underwriters for the IPO.

What is Nkarta's stock symbol?

Nkarta trades on the NASDAQ under the ticker symbol "NKTX."

When does Nkarta's quiet period expire?

Nkarta's quiet period expires on Wednesday, August 19th. Nkarta had issued 14,000,000 shares in its public offering on July 10th. The total size of the offering was $252,000,000 based on an initial share price of $18.00. During Nkarta's quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Nkarta?

Shares of NKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nkarta's stock price today?

One share of NKTX stock can currently be purchased for approximately $24.00.

How big of a company is Nkarta?

Nkarta has a market capitalization of $706.32 million. Nkarta employs 62 workers across the globe.

What is Nkarta's official website?

The official website for Nkarta is www.nkartatx.com.

How can I contact Nkarta?

Nkarta's mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-215-0385.

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.